Chronic obstructive pulmonary disease (COPD) and metabolic fatty liver syndromes: a dangerous but neglected liaison

Abstract

This perspective article aims at addressing the potential commonalities associated with chronic obstructive pulmonary disease (COPD) and the two metabolic fatty liver syndromes: nonalcoholic fatty liver disease (NAFLD) and metabolic (associated) fatty liver disease (MAFLD). To this end, we briefly review the definitions and burdens of COPD and NAFLD and highlight the differences in the diagnostic criteria of NAFLD and MAFLD. We also critically discuss the recent line of research trying to identify an association between COPD and NAFLD. Moreover, among the chief co-morbidities of COPD patients, we identify significant six that exert a major impact on the natural course of COPD: major cardiovascular events, cardiac arrhythmias, metabolic syndrome, obstructive sleep apnea, osteoporosis, and psychodepression. The potential role of NAFLD in each of these COPD co-morbidities is accurately examined based on published studies. We conclude that both COPD and NAFLD/MAFLD are heterogeneous systemic syndromes. While the complex mechanistic links underlying the association of NAFLD/MAFLD with COPD and its co-morbidities remain to be fully elucidated, we highlight that the diagnosis of metabolic fatty liver syndromes in patients with COPD might be clinically relevant, as it might allow identifying a subset of COPD individuals who, being at risk of severe clinical outcomes, would need more comprehensive treatment approaches.

Keywords

Cardiac arrhythmias / heart failure / major cardiovascular events / metabolic syndrome / osteoporosis / psychodepression

References

[1] Lonardo A,Ponz de Leon M.Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm?.Eur Respir J2017;49:1700546

[2] Agusti A.COPD as a systemic disease.COPD2008;5:133-8

[3] Vanni E,Mezzabotta L.Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander.Semin Liver Dis2015;35:236-49

[4] GOLD. 2022 Global initiative on Obstructive Pulmonary Disease (GOLD). Available from: www.goldcopd.org

[5] Lange P,Lahmar ZM,Bourdin A.Natural history and mechanisms of COPD.Respirology2021;26:298-321

[6] Zhang Y,Mutlu GM.More to explore: further definition of risk factors for COPD - differential gender difference, modest elevation in PM₂.₅, and e-cigarette use.Front Physiol2021;12:669152 PMCID:PMC8131967

[7] Agustí A.Natural history of COPD: gaps and opportunities.ERJ Open Res2017;3:00117-2017 PMCID:PMC5731770

[8] Negewo NA,McDonald VM.COPD and its comorbidities: impact, measurement and mechanisms.Respirology2015;20:1160-71

[9] Sin DD,Soriano JB.Mortality in COPD: role of comorbidities.Eur Respir J2006;28:1245-57

[10] Burke H.Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care.Eur Respir Rev2021;30:210041

[11] Barnett K,Norbury M.Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.The Lancet2012;380:37-43

[12] Vanfleteren LE,Groenen M.Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med2013;187:728-35

[13] Divo MJ,Poblador-Plou B.EpiChron - BODE collaborative groupchronic obstructive pulmonary disease (COPD) as a disease of early aging: evidence from the EpiChron Cohort.PLoS One2018;13:e0193143 PMCID:PMC5823454

[14] Ng R,Yao Z,Rosella LC.Smoking, drinking, diet and physical activity-modifiable lifestyle risk factors and their associations with age to first chronic disease.Int J Epidemiol2020;49:113-30 PMCID:PMC7124486

[15] Guerra S.The complex beginnings of chronic obstructive pulmonary disease.Am J Respir Crit Care Med2020;201:641-2 PMCID:PMC7068834

[16] Bush A.Impact of early life exposures on respiratory disease.Paediatr Respir Rev2021;40:24-32

[17] Quaderi SA.The unmet global burden of COPD.Glob Health Epidemiol Genom2018;3:e4 PMCID:PMC5921960

[18] Serra-Picamal X,Escarrabill J.Hospitalizations due to exacerbations of COPD: a big data perspective.Respir Med2018;145:219-25

[19] Roversi S,Fabbri LM.Breakthroughs in internal and respiratory medicine.The Lancet Respiratory Medicine2015;3:600-2

[20] Rabe KF,Suissa S.Cardiovascular disease and COPD: dangerous liaisons?.Eur Respir Rev2018;27:180057

[21] Corlateanu A,Mathioudakis AG.Chronic obstructive pulmonary disease and stroke.COPD2018;15:405-13

[22] Voulgaris A,Pataka A.Burden of Comorbidities in Patients with OSAS and COPD-OSAS Overlap Syndrome.Medicina (Kaunas)2021;57:1201 PMCID:PMC8623094

[23] Bitar AN,Ali IAH,Khan AH.Osteoporosis among patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of prevalence, severity, and therapeutic outcomes.J Pharm Bioallied Sci2019;11:310-20 PMCID:PMC6791086

[24] Zareifopoulos N,Spiropoulou A.Prevalence, contribution to disease burden and management of comorbid depression and anxiety in chronic obstructive pulmonary disease: a narrative review.COPD2019;16:406-17

[25] Staimez LR,Kim M,Saydah SH.Multimorbidity of four cardiometabolic and chronic pulmonary disease groups: prevalence and attributable fraction in US adults, 2007-2012.J Comorb2017;7:22-32 PMCID:PMC5556435

[26] Kotlyarov S.Lipid metabolism disorders in the comorbid course of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease.Cells2021;10:2978 PMCID:PMC8616072

[27] Ang L,Seow WJ.Association between previous lung diseases and lung cancer risk: a systematic review and meta-analysis.Carcinogenesis2021;42:1461-74

[28] Divo M.Multimorbidity in patients with chronic obstructive pulmonary disease.Clin Chest Med2020;41:405-19

[29] Feary JR,Smith CJ,Gibson JE.Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care.Thorax2010;65:956-62

[30] MacLeod M,Contoli M.Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact.Respirology2021;26:532-51

[31] Nielsen R,Omenaas ER.Excessive costs of COPD in ever-smokers. A longitudinal community study.Respir Med2011;105:485-93

[32] Sharafkhaneh A,Yu HJ.Burden of COPD in a government health care system: a retrospective observational study using data from the US veterans affairs population.Int J Chron Obstruct Pulmon Dis2010;5:125-32 PMCID:PMC2866562

[33] Villegas C, Paz-Zulueta M, Herrero-Montes M, Parás-Bravo P, Madrazo Pérez M. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review.Health Econ Rev2021;11:31 PMCID:PMC8369716

[34] Miller J,Agustí A.Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigatorsComorbidity, systemic inflammation and outcomes in the ECLIPSE cohort.Respir Med2013;107:1376-84

[35] Chatila WM,Minai OA,Make BJ.Comorbidities in chronic obstructive pulmonary disease.Proc Am Thorac Soc2008;5:549-55 PMCID:PMC2645334

[36] Divo M,de Torres JP.BODE Collaborative GroupComorbidities and risk of mortality in patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med2012;186:155-61

[37] Fabbri LM,Beghé B.Complex chronic comorbidities of COPD.Eur Respir J2008;31:204-12

[38] Fabbri LM.From COPD to chronic systemic inflammatory syndrome?.Lancet2007;370:797-9

[39] Su B,Fan H.Inflammatory markers and the risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis.PLoS One2016;11:e0150586 PMCID:PMC4841528

[40] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[41] Niederseer D,Aigner E,Datz C.NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations.J Clin Med2021;10:467 PMCID:PMC7865665

[42] Karlsen TH,Zelber-sagi S.The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.The Lancet2022;399:61-116

[43] Rodriguez-Roisin R,Huchon G.Inflammatory bowel diseases, chronic liver diseases and the lung.Eur Respir J2016;47:638-50

[44] Mantovani A,Vinco G.Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis.Diabetes Metab2019;45:536-44

[45] Kumar R,Anand U.Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations.J Clin Transl Hepatol2020;8:76-86 PMCID:PMC7132013

[46] Mantovani A,Mosca A.Complications, morbidity and mortality of nonalcoholic fatty liver disease.Metabolism2020;111S:154170

[47] Viglino D,Minoves M.Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.Eur Respir J2017;49:1601923

[48] Viglino D,Bailly S.Impact of non-alcoholic fatty liver disease on long-term cardiovascular events and death in chronic obstructive pulmonary disease.Sci Rep2018;8:16559 PMCID:PMC6224555

[49] Vestbo J,Coxson HO.ECLIPSE investigatorsEvaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE).Eur Respir J2008;31:869-73

[50] Viglino D,Almeras N.Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigatorsLow liver density is linked to cardiovascular comorbidity in COPD: an ECLIPSE cohort analysis.Int J Chron Obstruct Pulmon Dis2019;14:3053-61 PMCID:PMC6997198

[51] Hartman JE,Moore WH.HRCT characteristics of severe emphysema patients: Interobserver variability among expert readers and comparison with quantitative software.Eur J Radiol2021;136:109561

[52] Klooster K,Marquette CH.Endobronchial coil system versus standard-of-care medical management in the treatment of subjects with severe emphysema.Respiration2021;100:804-10 PMCID:PMC8491498

[53] Singhvi D.CT imaging and comorbidities in COPD: beyond lung cancer screening.Chest2021;159:147-53 PMCID:PMC8256436

[54] de Koning HJ,de Jong PA.Reduced lung-cancer mortality with volume ct screening in a randomized trial.N Engl J Med2020;382:503-13

[55] Toumazis I,Cao P.Cost-effectiveness evaluation of the 2021 US preventive services task force recommendation for lung cancer screening.JAMA Oncol2021;7:1833-42 PMCID:PMC8532037

[56] Regan EA,Murphy JR.Genetic epidemiology of COPD (COPDGene) study design.COPD2010;7:32-43 PMCID:PMC2924193

[57] Couper D,Han M.SPIROMICS Research GroupDesign of the subpopulations and intermediate outcomes in COPD study (SPIROMICS).Thorax2014;69:491-4 PMCID:PMC3954445

[58] Rinella ME.Nonalcoholic fatty liver disease: a systematic review.JAMA2015;313:2263-73

[59] Lonardo A,Alswat KA.History of nonalcoholic fatty liver disease.Int J Mol Sci2020;21:5888 PMCID:PMC7460697

[60] O'Hara J,Dhillon H.Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.JHEP Rep2020;2:100142 PMCID:PMC7397699

[61] Luukkonen PK,Ahlholm N.Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.J Hepatol2022;76:526-35 PMCID:PMC8852745

[62] Chen F,Rogers GB.Lean NAFLD: a distinct entity shaped by differential metabolic adaptation.Hepatology2020;71:1213-27

[63] Arrese M,Barrera F.Insights into nonalcoholic fatty-liver disease heterogeneity.Semin Liver Dis2021;41:421-34 PMCID:PMC8492194

[64] Friedman SL,Rinella M.Mechanisms of NAFLD development and therapeutic strategies.Nat Med2018;24:908-22 PMCID:PMC6553468

[65] Mantovani A,Petracca G.Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.2021;6:903-13

[66] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.Gut2021;70:962-9

[67] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.Gut2022;71:778-88

[68] Lonardo A.Renaming NAFLD to MAFLD: could the lde system assist in this transition?.J Clin Med2021;10:492 PMCID:PMC7866816

[69] Xian YX,Xu F.MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy.Chin Med J (Engl)2020;134:8-19 PMCID:PMC7862804

[70] Polyzos SA,Tsochatzis EA.Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease?.Metabolism2020;113:154413

[71] Miao L,Guo L.Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease.Journal of Clinical and Translational Hepatology2022;000:000-000

[72] Anstee QM,Tilg H.Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2018;15:425-39

[73] Gong H,Cheng F.Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis.J Int Med Res2021;49:3000605211047074 PMCID:PMC8489776

[74] Fudim M,Patel KV.Nonalcoholic fatty liver disease and risk of heart failure among medicare beneficiaries.J Am Heart Assoc2021;10:e021654 PMCID:PMC8751938

[75] Mantovani A,Benfari G.Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week.J Am Coll Cardiol2022;79:180-91

[76] Zhang Y,Zhang C.Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population.BMJ Open2015;5:e008204 PMCID:PMC4593152

[77] Lonardo A,Marchesini G,Loria P.Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.Dig Liver Dis2015;47:181-90

[78] Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions.Dig Liver Dis2017;49:471-83

[79] Lonardo A,Mantovani A.Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?.J Hepatol2018;68:335-52

[80] Ballestri S,Targher G.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.J Gastroenterol Hepatol2016;31:936-44

[81] Pang Y,Turnbull I.Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: a prospective study of 0.5 million people.Hepatology2018;68:1308-18 PMCID:PMC6220764

[82] Nasr P,Kechagias S.Modifiers of liver-related manifestation in the course of NAFLD.Curr Pharm Des2020;26:1062-78

[83] Destors M,Galerneau LM,Pepin JL.[Pathophysiology of obstructive sleep apnea syndrome and its cardiometabolic consequences].Presse Med2017;46:395-403

[84] Musso G,Olivetti C.Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. a systematic review and meta-analysis.Obes Rev2013;14:417-31

[85] Sundaram SS,Pan Z.Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease.J Hepatol2016;65:560-9 PMCID:PMC4992457

[86] Corey KE,Gelrud L.Obstructive sleep apnea is associated with nonalcoholic steatohepatitis and advanced liver histology.Dig Dis Sci2015;60:2523-8 PMCID:PMC4499481

[87] Bettini S,Fabris R.Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study.Eat Weight Disord2022;27:335-43 PMCID:PMC8019078

[88] Upala S,Wijarnpreecha K.Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis.J Bone Miner Metab2017;35:685-93

[89] Mantovani A,Zoppini G.Association between nonalcoholic fatty liver disease and reduced bone mineral density in children: a meta-analysis.Hepatology2019;70:812-23

[90] Lonardo A.Perspectives of nonalcoholic fatty liver disease research: a personal point of view.Explor of Med2020:1:[Online First].

[91] Gu Y,Hu Y,Shi J.Association between nonalcoholic fatty liver disease and depression: a systematic review and meta-analysis of observational studies.J Affect Disord2022;301:8-13

[92] Piazzolla G,Liotino V.Metabolic syndrome and chronic obstructive pulmonary disease (COPD): the interplay among smoking, insulin resistance and vitamin D.PLoS One2017;12:e0186708 PMCID:PMC5655494

[93] Rosato V,Dallio M.NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome.Int J Environ Res Public Health2019;16:3415 PMCID:PMC6765902

[94] Stols-Gonçalves D,Nieuwdorp M.NAFLD and atherosclerosis: two sides of the same dysmetabolic coin?.Trends Endocrinol Metab2019;30:891-902